Bernstein Reaffirms Outperform Rating on Thermo Fisher (TMO) After Investor Roadshow

Thermo Fisher Scientific Inc. (NYSE:TMO) ranks among the top picks for a retirement portfolio. On September 22, following talks with management, Bernstein reaffirmed its Outperform rating and $570 price target for Thermo Fisher Scientific Inc. (NYSE:TMO). Rafael Tejada, Head of Investor Relations at Thermo Fisher, took part in a non-deal roadshow in Toronto and Montreal with the firm’s analyst team.

According to Bernstein, although Thermo Fisher’s messaging was consistent with earlier discussions, the general atmosphere of these talks was “quite positive,” which made analysts “incrementally more positive” regarding the stock.

That said, the firm’s primary takeaway focused on investor attitude toward Thermo Fisher’s future performance, noting that, while most investors seem to be satisfied with the company’s 2025 forecast, some continue to question its projections for 2026 and 2027.

One of the top biotech and life sciences companies in the United States, Thermo Fisher Scientific Inc. (NYSE:TMO) offers a broad range of products and services. The company has grown significantly since its founding, mostly as a result of a number of well-timed acquisitions, such as those of Affymetrix and Life Technologies.

While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.